Dan Madden, Ilan Daskal
Cepheid has announced the appointment of Dan Madden to fill the position of executive vice president, CFO following the departure of Ilan Daskal, who had been in that post since only April.
Madden previously served as Cepheid's vice president and corporate controller. Daskal's departure, meanwhile, is not related to financial disclosure, accounting or legal matters, the company said in a statement.
Scott Patterson, Bruce Johnson, Paul Waring
Transgenomic has established a clinical-commercial advisory board to help guide the development of its ICE COLD-PCR technology for oncology applications. The board is headed by Scott Patterson, vice president of biomarker sciences at Gilead Sciences. Also joining the board are Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute and Harvard Medical School professor, and Paul Waring, director of the Center for Translational Pathology at the University of Melbourne.
Chad Cohen
Seattle-based Adaptive Biotechnologies has appointed Chad Cohen its chief financial officer, effective immediately. He replaces Dean Schorno, who is stepping down to pursue opportunities in the San Francisco Bay area where he lives. Cohen most recently was CFO for Zillow Group. He has been on Adaptive's board since March.
Daniel Farkas
Celmatix has appointed Daniel Farkas chief clinical laboratory officer for its new laboratory in Brooklyn, New York. He will be using his experience to lead the development of the new laboratory, which will conduct sequencing for the firm's genetic panel for fertility disorders.
Farkas has decades of experience in molecular diagnostics. He most recently worked as the lead laboratory director at Sequenom's clinical reference laboratories in San Diego; Grand Rapids, Michigan; and Morrisville, North Carolina. He has also served as president of the Association for Molecular Pathology; was the first professional to be certified in molecular diagnostics by the American Board of Bioanalysis; and has helped establish best practices in molecular pathology through his tenure on the College of American Pathologists' Molecular Pathology Resource Committee.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.